by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
After two decades in pharma and market access, I’ve seen launches succeed spectacularly, stumble unexpectedly, and sometimes collapse entirely. Through all of it, one lesson stands out above the rest: start with the system, not the science. Science dazzles. It wins...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pharma often treats access as a regulatory hurdle: tick the box, submit the dossier, wait for approval, and hope payers follow. Tech and consumer industries, by contrast, treat access as the game itself. That distinction is why there’s so much for pharma to learn....
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Pharma teams spend months crafting “value stories.” They’re sleek, glossy, and full of optimism. They highlight innovation, unmet need, and potential impact. And yet, when these stories reach payers, they often fall flat. The question is: why? The problem is simple....
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Every launch team asks: “Who benefits if we succeed?” Patients, shareholders, and sometimes physicians all make the list. But very few ask the opposite, arguably more important, question: “Who loses if we win?” This question is powerful because every new therapy...
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Market access is littered with myths that sound plausible — until they quietly drain millions from your launch budget. Believing them isn’t just harmless optimism; it’s expensive optimism. Let’s unpack the three most common offenders. Myth 1: Approval guarantees...
